Esperion Therapeutics (ESPR) News Today

Esperion Therapeutics (NASDAQ:ESPR) shares have decreased amid mixed headlines. Investors are weighing the landmark approval of its cholesterol drug NEXLETOL® in Japan and a bullish analyst rating against recent insider sales.

• Positive Sentiment: Japan’s Ministry of Health, Labour and Welfare approved NEXLETOL® (bempedoic acid) for hypercholesterolemia, marking entry into the world’s third-largest cardiovascular market and unlocking potential milestone payments and royalties for Esperion. Esperion stock rises after Japan approves cholesterol drug NEXLETOL
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating on ESPR and set a $16.00 price target—a 500% upside from current levels—underscoring strong confidence in Esperion’s growth prospects. HC Wainwright Reaffirms Buy Rating with $16 Price Target
• Neutral Sentiment: MarketBeat reports a consensus “Moderate Buy” rating from five brokerage firms covering ESPR, with four Buy ratings and one Hold. Esperion Therapeutics Receives Average Rating of “Moderate Buy” from Brokerages
• Negative Sentiment: General Counsel Benjamin Looker sold 6,267 shares at an average price of $2.80, reducing his stake by 1.57% and signaling potential caution from management insiders. General Counsel Sells $17,547.60 in Stock
• Negative Sentiment: CFO Benjamin Halladay sold 7,046 shares at about $2.81, trimming his position by roughly 1.46%, which may weigh on investor sentiment. Benjamin Halladay Sells 7,046 Shares of ESPR Stock